Drugs / POZETALDOGENE ORMESPARVOVEC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05394064 | Nov 2022 → Jun 2025 | adrenomyeloneuropathy | SwanBio Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | POZETALDOGENE ORMESPARVOVEC | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314866 ↗ |
| Known as | SBT101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05394064 ↗ |
| Route | Intrathecal | “Patients will receive a single dose of SBT101 via IT route” NCT05394064 ↗ |